AlphAIAlphAI — Financial news for AI agents
rttnews.com$WAT

Waters' BD OneFlow Tests Clear FDA Review; U.S. Launch Set For Spring 2027

Waters Corporation (WAT) announced FDA 510(k) clearance for two BD OneFlow tests, BD OneFlow LST and BD OneFlow B-CLPD T1, for identifying B-cell non-Hodgkin lymphoma. The tests showed 96.3% sensitivity and 98.2% specificity in detecting CLL. The system aims to improve efficiency and consistency in flow cytometry testing. Preorders are open, with a U.S. launch planned for spring 2027. WAT shares are currently trading at $475.21, down 0.31%.

Original reporting
rttnews.com
Published Nov 10, 2026, 5:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 5:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Waters' BD OneFlow Tests Clear FDA Review; U.S. Launch Set For Spring 2027 — source image
Source · rttnews.com
Decision brief

The 30-second read

$WATBullishMed
01

Why it matters

The FDA clearance marks the first U.S. approval for the BD OneFlow portfolio, paving the way for future test expansions.

02

Market read

Regulatory approval creates a new growth catalyst for Waters and may influence the broader diagnostics market.

03

What to watch

Adoption rates and reimbursement policies could affect commercialization speed

Relevance 7/10Novelty 8/10Timing: preorder now, launch spring 2027

Background

Waters Corporation develops analytical instruments and reagents for life‑science markets.

Company-level read

Ticker impact

$WATBullishMedium confidence
Context

Waters received FDA 510(k) clearance for two BD OneFlow flow cytometry tests, enabling U.S. commercialization.

Expected impact

likely upward pressure as investors price in future sales from the cleared tests

Evidence & confidence

FDA clearance is a material catalyst; the tests target common B‑cell NHL, offering sizable market opportunity.

Market effects

Sector

strengthens the flow‑cytometry and diagnostic reagents sector

Regional

adds a new U.S. product line for Waters

Global

potential to expand BD OneFlow portfolio worldwide

Counterpoint

What could challenge this read

Revenue impact may be delayed until 2027, limiting short‑term upside

Key entities

  • company
    Waters Corporation

    US‑listed provider of analytical instruments and reagents

  • product line
    BD OneFlow

    Standardized flow cytometry testing suite

Read at source← All news

StoryWaters receives FDA 510(k) clearance for BD OneFlow lymphoma diagnostic tests

Also covered by

2 outlets

Related articles

$WATMed

Waters receives FDA clearance for lymphoma diagnostic tests

Waters Corporation (NYSE:WAT) received FDA clearance for its lymphoma diagnostic tests, BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test, with 96.3% sensitivity and 98.2% specificity. The tests reduce manual steps by 95% and will be commercially available in the U.S. in spring 2027. According to NIH, 79,320 U.S. cases of non-Hodgkin lymphoma are expected in 2026.

investing.com
$WATMed

Waters Achieves FDA 510(k) Clearance for Ready-to-Use Flow Cytometry Clinical Tests for Leukemia and Lymphoma

Waters Corporation (NYSE: WAT) announced FDA 510(k) clearance for its BD OneFlow LST and BD OneFlow B-CLPD T1 Tests, which aid in diagnosing B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). The tests offer 96.3% sensitivity and 98.2% specificity. They reduce manual steps, improving workflow efficiency and reducing errors. The tests will be commercially available in the U.S. in spring 2027.

prnewswire.com
$WATMed

Waters CEO Udit Batra Announces Acquisition of MOBILion Systems to Expand Proteomics and AI-Driven Research Capabilities

Waters Corporation (NYSE: WAT) acquired MOBILion Systems, a developer of high-resolution ion mobility separation tech, to expand its proteomics market presence. The deal adds MOBILion's SLIM tech to Waters' mass spectrometry portfolio, aiming to enhance proteome coverage, sensitivity, and throughput. Waters estimates the proteomics market at $2B with high single-digit annual growth. The acquisition supports AI-driven research and potential clinical applications.

indianewengland.com
$WATHighAI 8/10

Bernstein raises Waters stock price target to $535 on earnings beat

Bernstein raised its price target on Waters Corp. (WAT) to $535 from $450, citing strong Q3 2026 results. Revenue grew 10% in constant currency, and adjusted EPS of $4.10 beat estimates. The company raised full-year 2026 guidance for revenue and EPS. Bernstein described the 2027 outlook as conservative, with mid-single-digit-plus organic growth expected. Other analysts also raised price targets following the earnings beat.

investing.com
$WATMed

KeyBanc raises Waters stock price target to $500 on guidance boost

KeyBanc raised its price target for Waters Corp. (WAT) to $500 from $460, citing strong Q3 results and raised guidance. WAT reported 10% revenue growth and 30.1% adjusted operating margin, exceeding estimates. The stock is up 52% in six months, trading near $460. Stifel also raised its target to $470 but maintained a Hold rating. WAT's full-year guidance was increased to 9.1%-9.7% growth, with AI and China growth cited as positive factors.

investing.com
$WATHighAI 8/10

Industry Roundup: Waters Posts Strong Third Quarter as LC–MS and Chromatography Consumables Drive Growth, Acquires Ion Mobility Pioneer MOBILion

Waters Corporation reported Q3 2026 revenue of $1.767B, up from $1.677B YoY. Analytical Sciences Division grew 8% to $703M, driven by LC-MS demand. The company acquired MOBILion Systems to expand its proteomics portfolio. Waters raised full-year guidance, expecting 9.1%-9.7% organic revenue growth. CEO Udit Batra cited strong execution and new products as growth drivers.

chromatographyonline.com